Variants of tumor necrosis factor-induced protein 3 gene are associated with left ventricular hypertrophy in hypertensive patients

Chinese Medical Journal

Volumn 124, Issue 10, 2011, Pages 1498-1503

  Xue, Hao ^a   Wang, Shu xia ^a   Wang, Xiao jian ^b   Xin, Ying ^b   Wang, Hu ^b   Song, Xiao dong ^b   Sun, Kai ^b   Wang, Yi bo ^b   Hui, Ru tai ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Hypertension; Left ventricular hypertrophy; Polymorphism; Tumor necrosis factor induced protein 3

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SYNAPSIN II; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INDUCED PROTEIN 3; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MARKER GENE; POPULATION RESEARCH; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; TNFAIP3 GENE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79957579807     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.10.011     Document Type: Article

References (25)

1. Schillaci G, Verdecchia P, Porcellati G, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35: 580-586.
2. Ueshima K, Yasuno S, Oba K, Fujimoto A, Ogihara T, Saruta T, et al. Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J Trial. Circ J 2009; 73: 1080-1085.
3. Fu Y, Katsuya T, Matsuo A, Yamamoto K, Akasaka H, Takami Y, et al. Relationship of bradykinin B2 receptor gene polymorphism with essential hypertension and left ventricular hypertrophy. Hypertens Res 2004; 27: 933-938.
4. Iwashima Y, Horio T, Kuroda S, Takishita S, Kawano Y. Influence of plasma aldosterone on left ventricular geometry and diastolic function in treated essential hypertension. Hypertens Res 2002; 25: 49-56.
5. Deschepper CF, Boutin GI, Zahabi A, Jiang Z. In search of cardiovascular candidate genes: interactions between phenotypes and genotypes. Hypertension 2002; 39 (2 Pt 2): 332-336.
6. Opipari AW Jr, Boguski MS, Dixit VM. The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J Biol Chem 1990; 265: 4705-14708.
7. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappa B signalling. Nature 2004; 430: 694-699.
8. Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, Lin A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci U S A 2001; 9: 6668-6673.
9. Cook SA, Novikov MS, Ahn Y, Matsui T, Rosenzweig A. A20 is dynamically regulated in the heart and inhibits the hypertrophic response. Circulation 2003; 108: 664-667.
10. De Keulenaer GW, Wang Y, Feng Y, Muangman S, Yamamoto K, Thompson JF, et al. Identification of IEX-1 as a biomechanically controlled nuclear factor-kappa B target gene that inhibits cardiomyocyte hypertrophy. Circ Res 2002; 90: 690-696.
11. Hirotani S, Otsu K, Nishida K, Higuchi Y, Morita T, Nakayama H, et al. Involvement of nuclear factor-kappa B and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 2002; 105: 509-515.
12. Li HL, Zhou ML, Wang D, Wang AB, Cai H, Sun LH, et al. Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation 2007; 115: 1885-1894.
13. Idel S, Dansky HM, Breslow JL. A20, a regulator of NFkappaB, maps to an atherosclerosis locus and differs between parental sensitive C57BL/6J and resistant FVB/N strains. Proc Natl Acad Sci U S A 2003; 100: 14235-14240.
14. Xue H, Wang S, Wang H, Sun K, Song X, Zhang W, et al. Atrial natriuretic peptide gene polymorphisms is associated with left ventricular hypertrophy in Hypertension. Clin Sci 2008; 114: 131-137.
15. Whitworth JA. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hyperten 2003; 21: 1983-1992.
16. Tajik AJ, Seward JB, Hagler DJ, Mair DD, Lie JT. Two-dimensional real-time ultrasonic imaging of the heart and great vessels. Technique, image orientation, structure identification, and validation Mayo. Clin Proc 1978; 53: 271-303.
17. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
18. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
19. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25: 1056-1062.
20. Ganau A, Devereux RB, Roman MJ, de Simone G., Pickering TG., Saba PS, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19: 1550-1558.
21. Leadon SA, Cerutti PA. A rapid and mild procedure of the isolation of DNA from mammalian cells. Anal Biochem 1982; 120: 282-288.
22. Yasukawa H, Hoshijima M, Gu Y, Nakamura T, Pradervand S, Hanada T, et al. Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways. J Clin Invest 2001; 108: 1459-1467.
23. Shaw J, Eydelnant IA, Kirshenbaum LA. Transgenic expression of A20 prevents cardiac cell death and myocardial dysfunction after myocardial infarction. Circulation 2007; 115: 1827-1829.
24. Boonyasrisawat W, Eberle D, Bacci S, Zhang YY, Nolan D, Gervino EV, et al. Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes. Diabetes 2007; 56: 499-505.
25. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet 2003; 361: 598-560.